Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Edelman

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Diabetes, Obesity & Metabolism|April 18, 2019
Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoringJeremy Pettus, Jasvinder Gill, Sachin Paranjape, et al.
Journal of Diabetes Science and Technology|January 17, 2019
A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 DiabetesMelanie Davies, Steve Bain, Guillaume Charpentier, et al.
Diabetes Care|July 2, 2003
Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetesVictoria Epshteyn, Katherine Morrison, Padma Krishnaswamy, et al.
Diabetes Research and Clinical Practice|April 14, 2017
Physician-patient communication at diagnosis of type 2 diabetes and its links to patient outcomes: New results from the global IntroDia® studyWilliam H Polonsky, Matthew Capehorn, Anne Belton, et al.
Diabetes, Obesity & Metabolism|December 8, 2020
Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m<sup>2</sup>Thomas Danne, Steven Edelman, Juan Pablo Frias, et al.
Diabetes Research and Clinical Practice|January 28, 2019
Physician-patient communication at prescription of an additional oral drug for type 2 diabetes and its links to patient outcomes - New findings from the global IntroDia® studySteven Edelman, Anne Belton, Susan Down, et al.
Diabetes Research and Clinical Practice|January 15, 2019
Physician experiences when discussing the need for additional oral medication with type 2 diabetes patients: Insights from the cross-national IntroDia® studySusan Down, Aus Alzaid, William H Polonsky, et al.
Diabetes Care|October 2, 2014
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot studyRobert R Henry, Julio Rosenstock, Steven Edelman, et al.
The Lancet. Diabetes & Endocrinology|September 18, 2020
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trialsPer-Henrik Groop, Paresh Dandona, Moshe Phillip, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Diabetes, Obesity & Metabolism|April 18, 2019
Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoringJeremy Pettus, Jasvinder Gill, Sachin Paranjape, et al.
Journal of Diabetes Science and Technology|January 17, 2019
A Randomized Controlled, Treat-to-Target Study Evaluating the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) Administered Using Either Device-Supported or Routine Titration in People With Type 2 DiabetesMelanie Davies, Steve Bain, Guillaume Charpentier, et al.
Diabetes Care|July 2, 2003
Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetesVictoria Epshteyn, Katherine Morrison, Padma Krishnaswamy, et al.
Diabetes Research and Clinical Practice|April 14, 2017
Physician-patient communication at diagnosis of type 2 diabetes and its links to patient outcomes: New results from the global IntroDia® studyWilliam H Polonsky, Matthew Capehorn, Anne Belton, et al.
Diabetes, Obesity & Metabolism|December 8, 2020
Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m<sup>2</sup>Thomas Danne, Steven Edelman, Juan Pablo Frias, et al.
Diabetes Research and Clinical Practice|January 28, 2019
Physician-patient communication at prescription of an additional oral drug for type 2 diabetes and its links to patient outcomes - New findings from the global IntroDia® studySteven Edelman, Anne Belton, Susan Down, et al.
Diabetes Research and Clinical Practice|January 15, 2019
Physician experiences when discussing the need for additional oral medication with type 2 diabetes patients: Insights from the cross-national IntroDia® studySusan Down, Aus Alzaid, William H Polonsky, et al.
Diabetes Care|October 2, 2014
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot studyRobert R Henry, Julio Rosenstock, Steven Edelman, et al.
The Lancet. Diabetes & Endocrinology|September 18, 2020
Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trialsPer-Henrik Groop, Paresh Dandona, Moshe Phillip, et al.
Pageof 3